Medicilon(SH:688202) Mei Ri Jing Ji Xin Wen·2025-09-04 15:55Core Viewpoint - Medisi (688202.SH) announced a legal dispute involving its wholly-owned subsidiary Medisi Puya, with a lawsuit amounting to approximately 159 million yuan filed by Hongxu Biopharmaceutical Technology [2][10] Group 1: Legal Dispute Details - The lawsuit is based on a technical service contract signed on December 18, 2020, where Medisi Puya was contracted to conduct non-clinical safety evaluations for Hongxu Biopharmaceutical's Class I biopharmaceuticals [8][9] - Hongxu Biopharmaceutical claims that Medisi Puya breached the contract and is seeking to terminate the contract, along with compensation for losses totaling approximately 1.5 billion yuan [9] - The total amount involved in the lawsuit is approximately 159 million yuan, which includes various claims such as breach of contract penalties and return of service fees [9] Group 2: Company Financial Performance - In the first half of 2025, Medisi reported revenue of approximately 540 million yuan, a year-on-year increase of 3.64% [5][6] - The net loss attributable to shareholders was approximately 12.9 million yuan, a reduction of 57.3 million yuan compared to the same period last year, primarily due to increased revenue and controlled costs [5][6] - The company’s total assets as of the end of the reporting period were approximately 2.83 billion yuan, with net assets of approximately 2.08 billion yuan [6] Group 3: Company Response to the Lawsuit - Medisi stated that it does not recognize the claims made by Hongxu Biopharmaceutical and will actively respond to the lawsuit, including potential counterclaims [10] - The company believes it has fulfilled its contractual obligations and that the project has received clinical trial approval from the National Medical Products Administration (NMPA) [10] - Medisi expects that the lawsuit will not have a significant impact on its daily operations and will continue to maintain stable business development [10]